Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Biogen's anti-tau Alzheimer's drug shows 38% slowing of decline at two years
00

Biogen's anti-tau Alzheimer's drug shows 38% slowing of decline at two years

Nov 17, 2026

At the Clinical Trials on Alzheimer's Disease conference on November 17, 2026, Biogen presented mid-stage clinical data showing that a 60-milligram twice-yearly dose of diranersen slowed cognitive decline in early Alzheimer's patients by 38% at two years, up from 26% at 18 months. Developed with Ionis Pharmaceuticals, diranersen silences tau-producing genes and is the first tau-targeting drug to demonstrate clinical efficacy, outperforming amyloid-targeting therapies like Leqembi and Kisunla.

Phase 2 diranersen efficacy results at two years

  • ▪The lowest 60-milligram twice-yearly spinal injection dose of Biogen and Ionis Pharmaceuticals' experimental anti-tau drug diranersen slowed early Alzheimer's disease cognitive decline by 38% at two years, compared to 26% at 18 months, presented November 17, 2026
  • ▪The two-year cognitive improvement from diranersen corresponds to a more than 1-point gain on the Clinical Dementia Rating-Sum of Boxes scoring system, which Biogen described as highly clinically meaningful
  • ▪The two-year diranersen trial data presented at the Clinical Trials on Alzheimer's Disease conference demonstrated cognitive and functional improvements across five of six study measures, including meal preparation and appointment tracking

Diranersen dose selection and side effect profile

  • ▪Biogen reported that higher diranersen doses of 115 milligrams slowed cognitive decline by only 9% to 14% at 18 months and were harder for patients to tolerate than the 60-milligram dose
  • ▪Side effects reported in Biogen's mid-stage diranersen trial were mostly mild to moderate headache or back pain related to lumbar puncture, with a small number of patients experiencing confusion and zero reports of dangerous brain swelling
  • ▪Biogen's head of clinical development Diana Gallagher said Biogen selected the 60-milligram twice-yearly spinal injection as the optimized diranersen dose for Phase 3 planning based on its combination of cognitive efficacy, administration frequency, and benefit-risk profile

Amyloid treatments and combination strategies

  • ▪Approved amyloid-targeting Alzheimer's treatments, including Biogen and Eisai's Leqembi and Eli Lilly's Kisunla, slow cognitive decline in early Alzheimer's disease patients by 25% to 30%
  • ▪Biogen's head of clinical development Diana Gallagher said Biogen is evaluating strategies to potentially use its amyloid-targeting drug Leqembi sequentially or in combination with its anti-tau drug diranersen for early Alzheimer's disease treatment

Alzheimer's background and tau targeting mechanism

  • ▪Biogen and Ionis Pharmaceuticals' experimental drug diranersen is designed to lower toxic tau protein in the brain by silencing the gene responsible for producing all forms of tau
  • ▪Biogen's head of clinical development Diana Gallagher said Biogen's diranersen trial is the first clinical study to demonstrate that lowering tau protein can slow Alzheimer's disease progression, whereas previous tau-targeting drugs failed to show clinical impact
  • ▪More than 55 million people globally have dementia, with approximately 60% of cases caused by Alzheimer's disease, which is characterized by the presence of amyloid and tau proteins in the brain

2 sources

Reuters
Biogen's anti-tau Alzheimer's drug benefits increase at 2 years | Reuters
View source article
Endpoints
Biogen says low dose of its experimental tau-reducing drug fares even better after nearly 2 years
View source article

Story comments

Loading comments…

Related entities

Tau protein

Topics

Drug developmentNeurodegenerative diseaseAlzheimer’s & dementiaClinical trialsEli LillyAlzheimer's diseasePharmaceutical IndustryCognitive decline